For new therapeutic avenues of ultra rare neurodevelopmental and neurodegenerative diseases: FOCUS (From mOleCUlar origins to treatment of IRF2BPL-related disorderS). Alliance4Rare 2023-2026 Eva Luise und Hosrt Köhler Stiftung Forschungsprojektförderung Klinik für Kinder- und Jugendmedizin, Universitätsmedizin Göttingen and BIMSB MDC Berlin (Berlin leader P. Lisowski).

To overcome technical challenges that prevent the widespread use of somatic gene therapy in the clinic: Gene Therapy of Rare Diseases (GetRadi). 2023-2027 EU-funded Marie Skłodowska-Curie Project, (Project partner R. Kuhn, project collaborator P. Lisowski)

To develop new treatments against mitochondrial DNA-associated rare and incurable diseases affecting children: CureMILS. A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrom. 2021-2024 Project funded by the European Joint Programme on Rare Diseases (EJP-RD project partner P. Lisowski).

To study genetic predisposition to rare neurodevelopmental disorders: Decoding genetic predisposition to rare neurodevelopmental disorders using genome engineering and patient-specific pluripotent stem cell based neuronal modeling. – 2017-2022 National Science Center Grant No. 20 16/22/M/NZ2/00548. NCN initiative announced under multilateral cooperation, utilising large-scale international research infrastructure (Project Leader P. Lisowski).

To study novel human neurodegenerative disorders: Functional study of the nonsense mutation in the IRF2BPL gene – an attempt to characterise a novel neurodegenerative human disease. 2018 – 2024 National Science Center OPUS Grant No. 2017/27/B/NZ1/02401 (Project Leader  P. Lisowski).

We are using patient stem cells and genome engineering to dissect the role of mitochondrial impairement in Huntington’s Disorder to identify counteracting strategies: Harnessing the mitochondrial vulnerability of neurons from Huntington’s Disease patients for uncovering novel therapeutic targets. 2020-2024 Deutsche Foschunsgemeinschaft (DFG) project #PR1527/5-1 (leading investigator P. Lisowski).


Genome editing technology development: Neurodegenerative disease modeling with multiplex genome editing (CRISPR/Cas9 systems) and human induced pluripotent stem cells (hiPSCs) – derived neurons. MDC/BIH research programme; 2014-2018 (Co-ivestigator: P. Lisowski)

Development of humanized neurodegenerative diseases models using TAL-Effector Nucleases (TALENs). DPN/MOB109/II/2012; 2013-2015 (Project Leader P. Lisowski).

Identification of differentally methylated regions (DMRs) in adipose tissue mesenchymal stem cells (AMSCs) using reduced representation bisulfite sequencing (RRBS) for improvement of somatic cell nuclear transfer (SCNT). Polish Scientific Committee Grant 2012/07/N/NZ9/02060;  2014-2016 (Principal Invesigator P. Lisowski)

Epigenomic regulations in the pathophysiology of chronic stress. Ministry of Science and Higher Education Grant IP2011 030371; 2012 – 2014 (Project Leader P. Lisowski)

NEWMOOD – New molecules in mood disorders: a genomic, neurobiological and systems approach in animal models and human disorder. 6th EU Framework Programme LSHMCT-2004-503474; 2005-2010 (Co-investigator P. Lisowski)